Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.57 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.54 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.54 |
| ▸ | CDK8 | P49336 | 3/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952226 | 0.81 | CYP2A6 (0.73) | CYP2A6PIP4K2APIP4K2BCYP17A1CYP11B1 | |
| SCHEMBL11008 | 0.81 | CYP2A6 (0.73) | CYP2A6PIP4K2APIP4K2BCYP17A1CYP11B1 | |
| SCHEMBL29953011 | 0.80 | CYP2A6 (0.67) | CYP2A6CDK8CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL3698604 | 0.80 | CYP2A6 (0.67) | CYP2A6CDK8CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL13354456 | 0.77 | PIP4K2A (0.58) | PIP4K2APIP4K2BCYP17A1CYP11B1CYP11B2 | |
| SCHEMBL3348627 | 0.77 | PIP4K2A (0.54) | CYP2A6PIP4K2APIP4K2BCYP17A1CYP11B1 | |
| SCHEMBL6655349 | 0.76 | NPC1 (0.59) | CYP2A6PIP4K2APIP4K2BCYP17A1CYP11B1 | |
| SCHEMBL31180051 | 0.75 | PTGS2 (0.38) | CYP2A6PIP4K2APIP4K2BCDK8PTGS2 | |
| SCHEMBL5850255 | 0.75 | NPC1 (0.79) | CYP2A6CYP17A1CYP11B1CYP11B2NPC1 | |
| SCHEMBL1356430 | 0.75 | PTGS2 (0.38) | CYP2A6PIP4K2APIP4K2BCDK8PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851199-B1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-7625889-B2 | Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070265309-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1851199-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | Aventis Pharmaceuticals, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006086705-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265309-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | HTR2A, HTR2B, HTR2C | CYP2A6 126/4885PIP4K2A 2895/4885PIP4K2B 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.